Advertisement

Rheumatology International

, Volume 39, Issue 1, pp 47–58 | Cite as

Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet’s disease associated uveitis: a systematic review

  • Ana Urruticoechea-Arana
  • Tatiana Cobo-Ibáñez
  • Virginia Villaverde-García
  • Montserrat Santos Gómez
  • Estíbaliz LozaEmail author
  • Kelly Vargas-Osorio
  • Leslie Fariñas Padrón
  • Federico Diaz-Gonzalez
  • Vanesa Calvo-Río
  • Ricardo Blanco
Systematic Review

Abstract

The aim of this study is to compare the efficacy and safety of biological therapy with cyclosporin A (CsA), azathioprine (AZA), or placebo in uveitis flares and other ocular outcomes in patients with Behçet disease. A comprehensive and sensitive search in MEDLINE, EMBASE, and the Cochrane Library was performed. We selected articles including: (1) adult patients with Behçet’s and uveitis; (2) on biological therapies; (3) placebo or active control with CsA or AZA; (4) analyzing efficacy (number of uveitis flares, macular edema, etc.) and/or safety outcomes. Meta-analyses, systematic reviews, clinical trials, and observational studies with > 10 patients were included. The selection, data collection and quality assessment (Oxford scale) was carried out by 2 reviewers independently. Nine articles of moderate quality were included (6 randomized clinical trials and 3 retrospective studies) involving 378 patients. Most of them, apart from the study drugs received systemic corticosteroids and other immunosuppressant drugs. Infliximab was more effective than CsA in reducing short-term uveitis flares and severe complications of retinal vasculitis in the long term. Rituximab was similar to a combination of cytotoxic drugs in improving inflammatory activity. In patients with active uveitis adalimumab was associated with a lower risk of uveitic flare or visual impairment, and in patients with inactive uveitis to a significantly lowered the risk of flare upon corticosteroid withdrawal. Secukinumab and daclizumab were not superior to placebo in reducing uveitis flares, like interferonα compared to other drugs. Our results highlight the need for better designed comparative studies on Behçet’s uveitis.

Keywords

Systematic literature review Uveitis Biologic therapy Behçet’s disease 

Notes

Author contributions

AU-A, RB and EL participated in the study design. MSG, KV-O, LFP and AU-A participates in the study selection and data collection. All of the authors took part in the rest of the study phases, contributed in this article discussion and reviewed the final version.

Funding

There was no specific funding for this work but for medical writing assistance that was provided by a grant from Merck Sharp & Dohme of Spain.

Compliance with ethical standards

Conflict of interest

RB has received grants/research supports from Abbvie, MSD, and Roche; Consultation fees/participation in company sponsored speaker´s bureau from AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD. EL has received grants/research supports from Abbvie, MSD, Roche, Pfizer, Bristol-Myers, MSD, Novartis, Astellas, Sanofi.

Supplementary material

296_2018_4193_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 18 KB)

References

  1. 1.
    Hatemi G, Yazici Y, Yazici H (2013) Behcet’s syndrome. Rheum Dis Clin North Am 39(2):245–261CrossRefGoogle Scholar
  2. 2.
    Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H (2007) Ocular features of Behcet’s disease: an international collaborative study. Br J Ophthalmol 91(12):1579–1582.CrossRefGoogle Scholar
  3. 3.
    Sakane T, Takeno M, Suzuki N, Inaba G. (1999) Behcet’s disease. N Engl J Med 341(17):1284–1291CrossRefGoogle Scholar
  4. 4.
    Kacmaz RO, Kempen JH, Newcomb C, Gangaputra S, Daniel E, Levy-Clarke GA et al (2008) Ocular inflammation in Behcet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146(6):828–836CrossRefGoogle Scholar
  5. 5.
    Leccese P, Ozguler Y, Christensen R, Esatoglu SN, Bang D, Bodaghi B et al (2018) Management of skin, mucosa and joint involvement of Behcet’s syndrome: a systematic review for update of the EULAR recommendations for the management of Behcet’s syndrome. Semin Arthritis Rheum.  https://doi.org/10.1016/j.semarthrit.2018.05.008 Google Scholar
  6. 6.
    Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F et al (2018) 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis 77(6):808–818Google Scholar
  7. 7.
    Ozdal PC, Ortac S, Taskintuna I, Firat E (2002) Long-term therapy with low dose cyclosporin A in ocular Behcet’s disease. Doc Ophthalmol 105(3):301–312CrossRefGoogle Scholar
  8. 8.
    Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A et al (1990) A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med 322(5):281–285CrossRefGoogle Scholar
  9. 9.
    Pivetti Pezzi P, Gasparri V, De Liso P, Catarinelli G. Prognosis in Behcet’s disease. Ann Ophthalmol. 1985;17(1):20–25.Google Scholar
  10. 10.
    Kaklamani VG, Kaklamanis PG (2001) Treatment of Behcet’s disease–an update. Semin Arthritis Rheum 30(5):299–312CrossRefGoogle Scholar
  11. 11.
    Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum 52(8):2478–2484CrossRefGoogle Scholar
  12. 12.
    Calvo-Rio V, Blanco R, Beltran E, Sanchez-Burson J, Mesquida M, Adan A et al (2014) Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet’s disease: a 1-year follow-up study of 124 patients. Rheumatology 53(12):2223–2231CrossRefGoogle Scholar
  13. 13.
    Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, Cordero-Coma M, Ortega G, Ortego N et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119(8):1575–1581CrossRefGoogle Scholar
  14. 14.
    Niccoli L, Nannini C, Benucci M, Chindamo D, Cassara E, Salvarani C et al (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology 46(7):1161–1164CrossRefGoogle Scholar
  15. 15.
    Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V et al (2014) Biological treatments in Behcet’s disease: beyond anti-TNF therapy. Mediators Inflamm 2014:107421CrossRefGoogle Scholar
  16. 16.
    U.S. National Library of Medicine (2018). Pages accessed at The U.S. National Institutes of Health at https://clinicaltrials.gov/. Accessed Aug 2018
  17. 17.
    World Health Organization. http://www.who.int/ictrp/search/en/. Accessed Aug 2017
  18. 18.
    Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewe R (2014) Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73(1):3–5CrossRefGoogle Scholar
  19. 19.
    Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M (2010) Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 94(3):284–288CrossRefGoogle Scholar
  20. 20.
    Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol. 2008;146(6):845e1–50e1.CrossRefGoogle Scholar
  21. 21.
    Hasanreisoglu M, Cubuk MO, Ozdek S, Gurelik G, Aktas Z, Hasanreisoglu B (2017) Interferon alpha-2a therapy in patients with refractory Behcet uveitis. Ocul Immunol Inflamm 25(1):71–75.CrossRefGoogle Scholar
  22. 22.
    Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P et al (2016) Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med 375(10):932–943CrossRefGoogle Scholar
  23. 23.
    Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183–1192CrossRefGoogle Scholar
  24. 24.
    Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777–787CrossRefGoogle Scholar
  25. 25.
    Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB et al (2007) A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet’s disease. Ocul Immunol Inflamm 15(2):63–70CrossRefGoogle Scholar
  26. 26.
    Lightman S, Taylor SR, Bunce C, Longhurst H, Lynn W, Moots R et al (2015) Pegylated interferon-alpha-2b reduces corticosteroid requirement in patients with Behcet’s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis 74(6):1138–1144CrossRefGoogle Scholar
  27. 27.
    Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A et al (2010) Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13(3):246–252CrossRefGoogle Scholar
  28. 28.
    Cordero-Coma M, Yilmaz T, Onal S (2013) Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm 21(1):19–27.CrossRefGoogle Scholar
  29. 29.
    Sobaci G, Erdem U, Durukan AH, Erdurman C, Bayer A, Koksal S et al (2010) Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet’s uveitis refractory to conventional treatments. Ophthalmology 117(7):1430–1435CrossRefGoogle Scholar
  30. 30.
    Park JY, Chung YR, Lee K, Song JH, Lee ES. (2015) Clinical experience of interferon Alfa-2a treatment for refractory uveitis in Behcet’s disease. Yonsei Med J 56(4):1158–1162.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Rheumatology DepartmentCan Misses HospitalIbizaSpain
  2. 2.Rheumatology DepartmentUniversity Hospital Infanta SofíaMadridSpain
  3. 3.Universidad EuropeaMadridSpain
  4. 4.Rheumatology DepartmentUniversity Hospital of MostolesMadridSpain
  5. 5.Rheumatology DepartmentSierrallana HospitalTorrelavegaSpain
  6. 6.Instituto de Salud Musculoesquelética, InMuscMadridSpain
  7. 7.Family and Community Medicine, Can Misses HospitalIbizaSpain
  8. 8.Rheumatology DepartmentUniversity Hospital of the Canary IslandsTenerifeSpain
  9. 9.University Hospital Marques of ValdecillaSantanderSpain

Personalised recommendations